GSK to Acquire Affinivax for ~$3.3B

Share this
GSK to Acquire Affinivax for ~$3.3B

GSK to Acquire Affinivax for ~$3.3B


  • GSK to acquire 100% of the outstanding shares of Affinivax with a total consideration of ~$3.3B incl. $2.1B up front & $0.6B upon achievement of milestones. The transaction is expected to close in Q3’22
  • The acquisition bolsters GSK’s vaccines R&D pipeline, provides access to Affinivax’s MAPS technology for pneumococcal diseases & expands its footprint in the Boston area. The acquisition will establish a strong portfolio of innovative vaccines & therapy, providing access to a 24-valent pneumococcal vaccine candidate currently in P-II trial
  • In the P-I/II trials, AFX3772 was well tolerated & showed good immune responses. The vaccine's use in paediatrics will initiate in 2022 & the P-III is expected to initiate shortly

Ref: GSK | Image: GSK

Click here to­ read the full press release 


Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions